These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 31985308

  • 1. Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis.
    Wang Q, Jiang C, Zhang Y, Zhang Y, Yue B, Zheng-Lin B, Zhao Y, Mauro MJ.
    Leuk Lymphoma; 2020 May; 61(5):1147-1157. PubMed ID: 31985308
    [Abstract] [Full Text] [Related]

  • 2. Association of Nilotinib With Cardiovascular Diseases in Patients With Chronic Myelogenous Leukemia: A National Population-Based Cohort Study.
    Huang CE, Lee KD, Chang JJ, Tzeng HE, Huang SH, Yu LH, Chen MC.
    Oncologist; 2024 Jan 05; 29(1):e81-e89. PubMed ID: 37561957
    [Abstract] [Full Text] [Related]

  • 3. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
    Lang K, McGarry LJ, Huang H, Dorer D, Kaufman E, Knopf K.
    Clin Lymphoma Myeloma Leuk; 2016 May 05; 16(5):275-285.e1. PubMed ID: 27013180
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Cardiovascular Adverse Events of Long-term Treatment with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Report from the Nagasaki CML Study Group.
    Chiwata M, Itonaga H, Sato S, Hashimoto M, Fujioka M, Kasai S, Sakamoto H, Toriyama E, Nakashima J, Kamijo R, Kitanosono H, Kobayashi Y, Horai M, Taguchi M, Matsuo M, Makiyama J, Takasaki Y, Matsuo E, Horio K, Ando K, Sawayama Y, Taguchi J, Kawaguchi Y, Tsushima H, Imanishi D, Imaizumi Y, Yoshida S, Jo T, Nonaka H, Moriuchi Y, Nagai K, Yokota KI, Hata T, Miyazaki Y.
    Intern Med; 2021 Jul 15; 60(14):2207-2216. PubMed ID: 33612681
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK, Ruterbusch JJ, Winn AN, George JA, Beebe-Dimmer JL, Schiffer CA.
    Cancer; 2021 Jan 01; 127(1):93-102. PubMed ID: 33119175
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
    Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E.
    Oncologist; 2019 Sep 01; 24(9):1253-1258. PubMed ID: 30944185
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [The importance of taking late cardiovascular toxicity induced by TKI into consideration in patients with CML].
    Takahashi N.
    Rinsho Ketsueki; 2016 Sep 01; 57(10):1956-1961. PubMed ID: 27725593
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
    Bhalla S, Tremblay D, Mascarenhas J.
    Clin Lymphoma Myeloma Leuk; 2016 Sep 01; 16(9):488-494. PubMed ID: 27406834
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.